These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33204076)

  • 61. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.
    Arnold FW; LaJoie AS; Brock GN; Peyrani P; Rello J; Menéndez R; Lopardo G; Torres A; Rossi P; Ramirez JA;
    Arch Intern Med; 2009 Sep; 169(16):1515-24. PubMed ID: 19752410
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled Trial (CAP-IT).
    Lyttle MD; Bielicki JA; Barratt S; Dunn D; Finn A; Harper L; Jackson P; Powell CVE; Roland D; Stohr W; Sturgeon K; Wan M; Little P; Faust SN; Robotham J; Hay AD; Gibb DM; Sharland M;
    BMJ Open; 2019 May; 9(5):e029875. PubMed ID: 31123008
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antibiotics for community-acquired pneumonia in adult outpatients.
    Pakhale S; Mulpuru S; Verheij TJ; Kochen MM; Rohde GG; Bjerre LM
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD002109. PubMed ID: 25300166
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prospective evaluation of the treatment and outcome of community-acquired pneumonia according to the Pneumonia Severity Index in VHA hospitals.
    Davydov L; Ebert SC; Restino M; Gardner M; Bedenkop G; Uchida KM; Bertino JS
    Diagn Microbiol Infect Dis; 2006 Apr; 54(4):267-75. PubMed ID: 16466891
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Corticosteroid treatment for community-acquired pneumonia--the STEP trial: study protocol for a randomized controlled trial.
    Blum CA; Nigro N; Winzeler B; Suter-Widmer I; Schuetz P; Briel M; Bingisser R; Zimmerli W; Ullmer E; Elsaesser H; Tarr P; Wirz S; Thomann R; Hofmann E; Rodondi N; Duplain H; Burki D; Mueller B; Christ-Crain M
    Trials; 2014 Jun; 15():257. PubMed ID: 24974155
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Guidelines-concordant empiric antimicrobial therapy and mortality in patients with severe community-acquired pneumonia requiring mechanical ventilation.
    Sakamoto Y; Yamauchi Y; Yasunaga H; Takeshima H; Hasegawa W; Jo T; Matsui H; Fushimi K; Nagase T
    Respir Investig; 2017 Jan; 55(1):39-44. PubMed ID: 28012492
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of systemic steroids in patients with severe community-acquired pneumonia.
    Garcia-Vidal C; Calbo E; Pascual V; Ferrer C; Quintana S; Garau J
    Eur Respir J; 2007 Nov; 30(5):951-6. PubMed ID: 17690125
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Outcome predictors of pneumonia in elderly patients: importance of functional assessment.
    Torres OH; Muñoz J; Ruiz D; Ris J; Gich I; Coma E; Gurguí M; Vázquez G
    J Am Geriatr Soc; 2004 Oct; 52(10):1603-9. PubMed ID: 15450034
    [TBL] [Abstract][Full Text] [Related]  

  • 69. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia.
    Rello J; Rodriguez A; Lisboa T; Gallego M; Lujan M; Wunderink R
    Crit Care Med; 2009 Feb; 37(2):456-62. PubMed ID: 19114916
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Does a 5-day course of antibiotics in elderly patients with community-acquired pneumonia achieve the established criteria of clinical stability?
    Flateau C; Dinia M; Raulet N; Sayegh S; Diamantis S; Jager M
    Infect Dis Now; 2021 Jun; 51(4):377-379. PubMed ID: 33096201
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Etiology and factors contributing to the severity and mortality of community-acquired pneumonia.
    Ishiguro T; Takayanagi N; Yamaguchi S; Yamakawa H; Nakamoto K; Takaku Y; Miyahara Y; Kagiyama N; Kurashima K; Yanagisawa T; Sugita Y
    Intern Med; 2013; 52(3):317-24. PubMed ID: 23370738
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of hospital-acquired pneumonia with multi-drug resistant organism by Buzhong Yiqi decoction based on Fuzheng Quxie classical prescription: study protocol for a randomized controlled trial.
    Deng D; Chen Z; Jia L; Bu J; Ye M; Sun L; Gen Y; Zhang W; Chen G; Fang B
    Trials; 2019 Dec; 20(1):817. PubMed ID: 31888702
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience.
    Ioachimescu OC; Ioachimescu AG; Iannini PB
    Int J Antimicrob Agents; 2004 Nov; 24(5):485-90. PubMed ID: 15519482
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-acquired Pneumonia.
    Luna CM; Palma I; Niederman MS; Membriani E; Giovini V; Wiemken TL; Peyrani P; Ramirez J
    Ann Am Thorac Soc; 2016 Sep; 13(9):1519-26. PubMed ID: 27398827
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Priority for Treatment and Intensive Care of Patients With Non-Severe Community-Acquired Pneumonia.
    Li HY; Guo Q; Song WD; Zhou YP; Li M; Chen XK; Liu H; Peng HL; Yu HQ; Chen X; Liu N; Lü ZD; Liang LH; Zhao QZ; Jiang M
    Am J Med Sci; 2018 Oct; 356(4):329-334. PubMed ID: 30360800
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Impact of prior pulmonary tuberculosis in treatment outcomes of HCAP and CAP patients in intensive care units.
    Lin FM; Feng JY; Fang WF; Wu CL; Yu CJ; Lin MC; Ku SC; Chen CW; Tu CY; Yang KY
    J Microbiol Immunol Infect; 2019 Apr; 52(2):320-328. PubMed ID: 30245205
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Community-acquired pneumonia in patients with chronic obstructive pulmonary disease requiring admission to the intensive care unit: risk factors for mortality.
    Cilli A; Erdem H; Karakurt Z; Turkan H; Yazicioglu-Mocin O; Adiguzel N; Gungor G; Bilge U; Tasci C; Yilmaz G; Oncul O; Dogan-Celik A; Erdemli O; Oztoprak N; Samur AA; Tomak Y; Inan A; Karaboga B; Tok D; Temur S; Oksuz H; Senturk O; Buyukkocak U; Yilmaz-Karadag F; Ozcengiz D; Karakas A; Savasci U; Ozgen-Alpaydın A; Kilic E; Elaldi N; Bilgic H
    J Crit Care; 2013 Dec; 28(6):975-9. PubMed ID: 24075301
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and safety of Shengjiang Xiexin decoction in prophylaxis of chemotherapy-related diarrhea in small cell lung cancer patients: study protocol for a multicenter randomized controlled trial.
    Deng C; Lou Y; Gao Y; Deng B; Su F; Jia L
    Trials; 2020 May; 21(1):370. PubMed ID: 32357899
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Functional status and mortality prediction in community-acquired pneumonia.
    Jeon K; Yoo H; Jeong BH; Park HY; Koh WJ; Suh GY; Guallar E
    Respirology; 2017 Oct; 22(7):1400-1406. PubMed ID: 28513919
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Interventions for preventing critical illness polyneuropathy and critical illness myopathy.
    Hermans G; De Jonghe B; Bruyninckx F; Van den Berghe G
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD006832. PubMed ID: 24477672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.